Travoprost 004% sterile ophthalmic solution — Competitive Intelligence Brief

Travoprost 004% sterile ophthalmic solution (Travoprost 004% sterile ophthalmic solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin F analog. Area: Ophthalmology.

marketed Prostaglandin F analog Prostaglandin F (FP) receptor Ophthalmology Small molecule

Target snapshot

Travoprost 004% sterile ophthalmic solution (Travoprost 004% sterile ophthalmic solution) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Travoprost is a prostaglandin F analog that binds to prostaglandin F (FP) receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Travoprost 004% sterile ophthalmic solution TARGET	Travoprost 004% sterile ophthalmic solution	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Prostaglandin F analog	Prostaglandin F (FP) receptor
Preservative-free bimatoprost	Preservative-free bimatoprost	Association for Innovation and Biomedical Research on Light and Image	marketed	Prostaglandin F analog	Prostaglandin F (FP) receptor
Dorzolamide-timolol and latanoprost	Dorzolamide-timolol and latanoprost	Laboratorios Sophia S.A de C.V.	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog	Carbonic anhydrase II (dorzolamide), beta-1 and beta-2 adrenergic receptors (timolol), prostaglandin F receptor (latanoprost)
Preserved Bimatoprost 0.01%	Preserved Bimatoprost 0.01%	Universitaire Ziekenhuizen KU Leuven	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Topical latanoprost 0.005%	Topical latanoprost 0.005%	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
travoprost 0.004% (drug)	travoprost 0.004% (drug)	University Hospital, Basel, Switzerland	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
IOPIZE© Latanoprost eyedrops	IOPIZE© Latanoprost eyedrops	University of Catanzaro	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin F analog class)

1. Allergan · 8 drugs in this class
2. CHU de Quebec-Universite Laval · 2 drugs in this class
3. Association for Innovation and Biomedical Research on Light and Image · 2 drugs in this class
4. Kasr El Aini Hospital · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
7. Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
8. SpyGlass Pharma, Inc. · 1 drug in this class
9. Tun Hussein Onn National Eye Hospital · 1 drug in this class
10. Universitaire Ziekenhuizen KU Leuven · 1 drug in this class